| La Cliniquita, Inc. | |
|
6505 Rosemead Blvd Ste 106 Pico Rivera CA 90660-3542 | |
| (562) 373-2007 | |
| Not Available |
| Full Name | La Cliniquita, Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 6505 Rosemead Blvd Ste 106, Pico Rivera, California |
| Authorized Official Name and Position | Cristina Idalie Garcia (OWNER) |
| Authorized Official Contact | 5623732007 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| La Cliniquita, Inc. 6505 Rosemead Blvd Ste 106 Pico Rivera CA 90660-3542 Ph: () - | La Cliniquita, Inc. 6505 Rosemead Blvd Ste 106 Pico Rivera CA 90660-3542 Ph: (562) 373-2007 |
| NPI Number | 1679024467 |
|---|---|
| Provider Enumeration Date | 10/17/2016 |
| Last Update Date | 10/17/2016 |
| Medicare PECOS PAC ID | 4486930229 |
|---|---|
| Medicare Enrollment ID | O20170411000972 |
News Archive
Concussions and the issues that can occur following one, continue to be a serious problem for football players. However, one simple game strategy: proper helmet fit, may be one of the easiest game winners for prevention, say researchers presenting their study at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Francisco.
Today, after four arduous years of examinations, graduating medical doctors will report to their residency programs. Armed with stethoscopes and scalpels, they're preparing to lead the charge against disease in its ravaging, chimerical forms. They carry with them the classic tomes: Harrison's Principles of Internal Medicine and Gray's Anatomy. But I have an unlikely addition for their mental rucksacks: "Grimm's Fairy Tales".
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679024467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | A123276 (California) | Primary |
| Provider Name | Cristina Idalie Garcia |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326391004 PECOS PAC ID: 0941525919 Enrollment ID: I20150730013220 |
News Archive
Concussions and the issues that can occur following one, continue to be a serious problem for football players. However, one simple game strategy: proper helmet fit, may be one of the easiest game winners for prevention, say researchers presenting their study at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Francisco.
Today, after four arduous years of examinations, graduating medical doctors will report to their residency programs. Armed with stethoscopes and scalpels, they're preparing to lead the charge against disease in its ravaging, chimerical forms. They carry with them the classic tomes: Harrison's Principles of Internal Medicine and Gray's Anatomy. But I have an unlikely addition for their mental rucksacks: "Grimm's Fairy Tales".
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.
› Verified 2 days ago
News Archive
Concussions and the issues that can occur following one, continue to be a serious problem for football players. However, one simple game strategy: proper helmet fit, may be one of the easiest game winners for prevention, say researchers presenting their study at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Francisco.
Today, after four arduous years of examinations, graduating medical doctors will report to their residency programs. Armed with stethoscopes and scalpels, they're preparing to lead the charge against disease in its ravaging, chimerical forms. They carry with them the classic tomes: Harrison's Principles of Internal Medicine and Gray's Anatomy. But I have an unlikely addition for their mental rucksacks: "Grimm's Fairy Tales".
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.
› Verified 2 days ago
Beverlycare Pico Rivera Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8862 Whittier Blvd, Pico Rivera, CA 90660 Phone: 323-725-5073 | |
Payam Marouni Md Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8338 Rosemead Blvd, Pico Rivera, CA 90660 Phone: 562-942-1200 Fax: 562-942-1200 | |
Friends Of Family Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5062 Rosemead Blvd, Pico Rivera, CA 90660 Phone: 562-801-2287 Fax: 562-690-3182 | |
Eldorado Community Service Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8207 Whittier Blvd, Pico Rivera, CA 90660 Phone: 562-692-2522 Fax: 562-695-0413 | |
Gemma Th Ko,md. Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4511 Rosemead Blvd, Pico Rivera, CA 90660 Phone: 562-692-3388 | |
San Martin De Porres Medical Center Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9315 Telegraph Rd, Pico Rivera, CA 90660 Phone: 562-654-6855 | |
San Martin De Porres Medical Clinic Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9315 Telegraph Rd, Pico Rivera, CA 90660 Phone: 562-654-6855 Fax: 562-654-6856 |